表达黑色素瘤抗原-A3重组质粒的免疫原性研究

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (825 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To construct a recombinant lung cancer DNA vaccine with high expression antigen MAGE-A3 in lung cancer and to evaluate its immunogenicity.Methods MAGE-A3 genes were fused with GM-CSF by F2A and cloned into pVAX1 to construct the gene vaccine ppVAX1-MAGE-A3-F2A-GM-CSF. After the gene vaccine was transfected into 293T cells, the expression of the gene vaccine was detected by Western blot and ELISA. Then, the gene vaccine and the control group were injected into the mouse model, and the immune activity was detected by ELISA and ELISPOT.Results Gene vaccine pVAX1-MAGE-A3-F2A-GM-CSF was constructed, and the expression of the antigen was confirmed. After the mice were vaccinated with the gene vaccine, the test Results of ELISA and ELISPOT showed that pVAX1-MAGE-A3-F2A-GM-CSF induced both humoral immune response and cellular immune response compared with the control group.Conclusions pVAX1-MAGE-A3-F2A-GM-CSF can induce both humoral immune response and cellular immune response, and its potential anti-tumor effect needs to be further studied.

Key words： MAGE-A3 lung cancer granulocyte-macrophage colony-stimulating factor gene vaccine

Received: 15 May 2016

ZTFLH:

R392.11

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YUE Honghong
	ZHAO Liang
	and JIANG Wei

Cite this article:

YUE Honghong,ZHAO Liang,and JIANG Wei. Immunogenicity analysis of recombinant plasmid harboring MAGE-A3 antigens[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(12): 1245-1248.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I12/1245

[1]	Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: advances and prospects[J]. Am J Clin Exp Immunol, 2016, 5(1):1-20.
[2]	胡兴胜. 内皮生长因子受体突变非小细胞肺癌精准个体化治疗[J].武警医学,2015,26(8):757-764.
[3]	Guo C, Manjili MH, Subjeck J R, et al. Therapeutic cancer vaccines: past, present, and future[J]. Adv Cancer Res, 2013, 119:421-475.
[4]	Farkona S, Diamandis E P, Blasutig I M. Cancer immunotherapy: the beginning of the end of cancer?[J].BMC Med, 2016, 14(1):73.
[5]	武爱文,谢冰莹,季加孚. 胃癌个体化靶向治疗、免疫治疗及其研究进展[J].武警医学,2015,26(9):865-868.
[6]	Yong X, Xiao Y F, Luo G, et al. Strategies for enhancing vaccine-induced CTL antitumor immune responses[J]. J Biomed Biotechnol, 2012, 2012:605-645.
[7]	Lee S H, Danishmalik S N, Sin J I. DNA vaccines, electroporation and their applications in cancer treatment[J]. Hum Vaccin Immunother, 2015, 11(8):1889-1900.
[8]	Grunwald T, Ulbert S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases[J].Clin ExpVaccine Res, 2015, 4(1):1-10.
[9]	Domingues D, Turner A, Silva M D, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies[J]. Immunotherapy, 2014, 6(11):1221-1235.
[10]	Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice[J]. Immunotherapy, 2015, 7(6):683-704.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 711-712.